160807-49-8
160807-49-8 結(jié)構(gòu)式
基本信息
靛玉紅-3' -單肟
Indirubin-3′
INDIRUBIN-3'-OXIME
Indirubine-3'-oxime
INDIRUBIN-3'-MONOXIME
INDIRUBIN-3’-MONOOXIME
3-[1,3-DIHYDRO-3-(HYDROXYIMINO)-2H-INDOL-2-YLIDENE]-1,3-DIHYDRO-2H-INDOL-2-ONE
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
應(yīng)用領(lǐng)域
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱(chēng) | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/03/03 | S2009 | 靛玉紅-3' -單肟 Indirubin-3'-monoxime | 160807-49-8 | 5mg | 873.85元 |
| 2026/03/03 | S2009 | 靛玉紅-3' -單肟 Indirubin-3'-monoxime | 160807-49-8 | 25mg | 2673.81元 |
| 2025/12/22 | HY-19807 | 靛玉紅-3' -單肟 Indirubin-3'-monoxime | 160807-49-8 | 5mg | 500元 |
常見(jiàn)問(wèn)題列表
| Target | Value |
|
CDK5-P35
(Cell-free assay) | 0.065 μM |
|
CDK1-cyclinB
(Cell-free assay) | 0.18 μM |
|
CDK2-cyclinE
(Cell-free assay) | 0.25 μM |
|
CDK2-cyclinA
(Cell-free assay) | 0.44 μM |
|
CDK4-cyclinD1
(Cell-free assay) | 3.33 μM |
Indirubin-3'-monoxime inhibits GSK-3β by competing with ATP, with K i of 0.85 μM, and K m of 110 μM. Indirubin-3'-monoxime also inhibits tau phosphorylation by GSK-3β, with an IC 50 value of around 100 nM. Indirubin-3'-monoxime completely inhibits the phosphorylation of the AT100 epitope. Indirubin-3'-monoxime inhibits vascular smooth muscle cell (VSMC) proliferation with IC 50 of ～2 μM. Indirubin-3'-monoxime blunts migration of VSMC stimulated with the PDGF. Indirubin-3'-monoxime interferes with the migratory response in VSMC, and also suppresses the production of pro-migratory LT in monocytes. Moreover, Indirubin-3'-monoxime inhibits 5-lipoxygenase (5-LO) product synthesis in monocytes and neutrophils, with the same potency (IC 50 =5.0±1.1 and 3.7±1.2 μM, respectively). Indirubin-3'-monoxime is an inhibitor of 5-LO, with IC 50 of 7.8-10 μM in cell-free assay.
Indirubin-3'-monoxime (0.1, 0.2 and 0.4 mg/kg, i.p) dose dependently reverses the cognitive impairment and combats the elevated oxidative stress markers in HFD fed mice. Indirubin-3'-monoxime also dose dependently lowers the serum glucose, TGs, TC and insulin levels, and improves the β-cell functioning in HFD fed mice. Moreover, Indirubin-3'-monoxime treatment significantly decreases HOMA-IR levels compared to HFD group. Indirubin-3'-monoxime (0.4 mg/kg) significantly attenuates the increased EL in the HFD group.